Tier 1 — highest
Magnesium citrate supplementation decreased blood pressure and HbA1c in normomagnesemic subjects with metabolic syndrome: a 12-week, placebo-controlled, double-blinded pilot trial
Magnesium research
2021
34(3):130-139
Bibliography
- PubMed
- PMID 34859788
- Funding
- Funding is not specified in the indexed abstract or accessible funding metadata. Consult the original publication for the declaration.
- Competing interests
- A competing-interest declaration is not available in the indexed abstract or accessible disclosure metadata.
Study snapshot
| Design | Randomized controlled clinical trial |
|---|---|
| Model | Human participants |
| Sample | 24 participants with metabolic syndrome and normal serum magnesium |
| Intervention | 400 mg/day elemental magnesium as citrate or placebo |
| Duration | 12 weeks |
| Endpoints | Blood pressure; HbA1c; Vitamin D and magnesium status |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
Biohack Blueprint Research
